A groundbreaking new medication, often referred to as ‘Viagra for women’, has recently become available, approximately thirty years after men gained access to the ‘little blue pill’.
Viagra, scientifically known as Sildenafil, emerged in 1989 due to an unexpected discovery and has since enhanced the sexual experiences of countless individuals worldwide.
Originally, medical researchers were on the hunt for an angina treatment when they inadvertently addressed the long-standing issue of erectile dysfunction (ED).
For the past three decades, this drug has significantly improved male sexual performance, amassing substantial revenue for Pfizer, the pharmaceutical company behind the iconic ‘little blue pill’.
The Cleveland Clinic explains that its effectiveness lies in boosting blood flow to the penis, thereby aiding in the maintenance of an erection.
In recent times, researchers have been on a quest to develop a female counterpart, as Sildenafil hasn’t shown similar effects for women.
Psychology Today suggests that the lack of efficacy in women is linked to differences in brain function between genders.
Despite anatomical differences, pharmaceutical companies initially theorized that increasing blood flow to the female genital area might mirror the effects seen in men.
The aim was to trigger physical arousal, subsequently leading to psychological arousal.
However, this approach was unsuccessful. Research indicated that while men respond to medically induced physical arousal with increased psychological arousal, women’s brains do not follow the same pattern.
This implies that “if a man is physically aroused, he will also become psychologically aroused. Women, however, seem to require more than just physical stimulation.”
Despite the setbacks faced by pharmaceutical companies, Daré Bioscience, a women’s health biotech group, remained undeterred in their pursuit to address what they term ‘one of medicine’s most persistent gender gaps.’
Based in Southern California, the organization reports that around 20 million women struggle with sexual arousal. Their innovative cream, ‘DARE TO PLAY’, promises to rapidly enhance blood flow to the vagina and stimulate sexual arousal, purportedly within 10 minutes.
Interestingly, this cream utilizes sildenafil, the same ingredient found in Viagra, but is applied topically to ‘enhance the body’s natural arousal response without systemic effects, providing women with a new, evidence-based tool to take charge of their sexual health’, according to the organization.
Sabrina Martucci Johnson, President and CEO of Daré Bioscience, commented: “When Viagra was approved in 1998, it revolutionized sexual medicine for men. But for women, comparable progress on enhancing the natural arousal sensations has stalled for nearly three decades.
“We believe DARE to PLAY represents a long overdue correction, giving women an option to reconnect with their own bodies, their pleasure, and their confidence, using science that finally recognizes their needs.”
This marks the introduction of the first female arousal cream of its kind, which is reported to take effect within 10 to 15 minutes before engaging in sexual activities.
Clinical trials indicated no side effects when compared to placebos.
The product is now available for pre-order via prescription in ten U.S. states, including Utah, New Jersey, Connecticut, Pennsylvania, Florida, Rhode Island, Indiana, Oregon, Missouri, and New Hampshire.